Title:
|
Nanomedicine in non-small cell lung cancer: from conventional treatments to immunotherapy
|
Author:
|
Fornaguera Puigvert, Cristina; Borrós i Gómez, Salvador; García-Fernández, Coral
|
Other authors:
|
Universitat Ramon Llull. IQS |
Abstract:
|
Non-small cell lung cancer (NSCLC) remains the most common cause of cancer-related mortality. The heterogeneous nature of this disease hinders its diagnosis and treatment, requiring continuous advances in research aiming to understand its intricate nature. Consequently, the retrospective analysis of conventional therapies has allowed the introduction of novel tools provided by nanotechnology, leading to considerable improvements in clinical outcomes. Furthermore, the development of novel immunotherapies based on the recently understood interaction of the immune system with the tumor highlights the real possibility of definitively treating NSCLC from its early stages. Novel engineering approaches in nanomedicine will enable to overcome the intrinsic limits of conventional and emerging therapies regarding off-site cytotoxicity, specificity, resistance mechanisms, and administration issues. The convergence point of these therapies with nanotechnology lays the foundation for achieving currently unmet needs. |
Publication date:
|
2020-06 |
Subject (UDC):
|
616 - Patologia. Medicina clínica. Oncologia |
Subject(s):
|
Pulmons--Càncer Immunoteràpia Nanomedicina Vacunes contra el càncer Quimioteràpia Non-small cell lung cancer Immunotherapies Nanomedicine Cancer vaccine Chemotherapy |
Rights:
|
L'accés als continguts d'aquest document queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons:http://creativecommons.org/licenses/by/4.0/
© L'autor/a |
Pages:
|
26 p. |
Document type:
|
Article Article - Published version |
DOI:
|
https://doi.org/10.3390/cancers12061609
|
Published by:
|
MDPI
|
Publish at:
|
Cancers. Vol.12, n.6 (2020), 1609
|
Share:
|
|